Loratadine use for the prevention of filgrastim-induced bone pain among patients with cancer receiving chemotherapy at National Hospital, Abuja

INTERVENTION: Placebo Tabs Loratadine CONDITION: ; Cancer Cancer PRIMARY OUTCOME: To determine the incidence of cancer patients who develop filgrastim‐induced bone pain in the loratadine and placebo groups. SECONDARY OUTCOME: ‐ To determine the effect of prophylactic loratadine on the severity, duration, and interference with daily activities of filgrastim‐induced bone pain compared to placebo. ; ‐ To assess factors associated with the development of filgrastim‐induced bone pain. ; ‐ To determine the safety profile of loratadine. ; ‐ To identify perceived effectiveness of treatment options previously used for filgrastim‐induced bone pain. INCLUSION CRITERIA: 1. Patients with ECOG (Eastern Cooperative Oncology Group) performance status of 0 and 1 2. Patients to receive at least 1 cycle of systemic chemotherapy with prophylaxis filgrastim support. 3. Patients that are 18 years or older 4. Patients with stage I to III cancer. 5. Patients with prior history of filgrastim‐induced bone pain 6. Patients on concurrent chemoradiation.